

1  
2  
3  
4 *Cocaine modulates both, glutaminase gene expression and*  
5  
6 *glutaminase activity in the brain of cocaine-sensitized mice*  
7  
8  
9

10  
11  
12  
13 Eduardo Blanco<sup>a,b\*#</sup>, José Ángel Campos-Sandoval<sup>d#</sup>, Ana Palomino<sup>a</sup>, María Jesús  
14 Luque-Rojas<sup>a</sup>, Ainhoa Bilbao<sup>a,c</sup>, Juan Suárez<sup>a</sup>, Javier Márquez<sup>d\*</sup>, Fernando Rodríguez de  
15 Fonseca<sup>a\*</sup>  
16  
17  
18

19  
20  
21 <sup>a</sup>Fundación IMABIS, Laboratorio de Medicina Regenerativa, Hospital Regional  
22 Universitario Carlos Haya, Málaga 29010, Spain  
23

24 <sup>b</sup>Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento,  
25 Facultad de Psicología, Universidad de Málaga, Campus de Teatinos s/n, Málaga  
26 29071, Spain  
27  
28

29 <sup>c</sup>Department of Psychopharmacology, Central Institute of Mental Health, Mannheim  
30 8159, Germany  
31  
32

33 <sup>d</sup>Departamento de Biología Molecular y Bioquímica, Facultad de Ciencias, Laboratorio  
34 de Química de Proteínas, Universidad de Málaga, Campus de Teatinos s/n, Málaga  
35 29071, Spain  
36  
37

38 <sup>#</sup>These authors contributed equally to the present study.  
39

40 Corresponding authors:  
41  
42

43  
44 <sup>\*</sup>Eduardo Blanco, Fundación IMABIS, Hospital R.U. Carlos Haya, Laboratorio de  
45 Medicina Regenerativa, Pabellón de Gobierno, sótano, Málaga 29010, Spain; Tel: +34  
46 952 61 40 12; e-mail: [eduardo.blanco@fundacionimabis.org](mailto:eduardo.blanco@fundacionimabis.org), [eduardo.blanco@uma.es](mailto:eduardo.blanco@uma.es)  
47  
48  
49

50  
51 <sup>\*</sup>Javier Márquez, Universidad de Málaga, Facultad de Ciencias, Departamento de  
52 Biología Molecular y Bioquímica, Laboratorio de Química de Proteínas, Campus de  
53 Teatinos s/n, Málaga 29071, Spain; Tel: +34 952 13 20 24; e-mail: [marquez@uma.es](mailto:marquez@uma.es)  
54  
55  
56

57  
58 <sup>\*</sup>Fernando Rodríguez de Fonseca, Fundación IMABIS, Hospital R.U. Carlos Haya,  
59 Laboratorio de Medicina Regenerativa, Pabellón de Gobierno, sótano, Málaga 29010,  
60 Spain; Tel: +34 952 61 40 12; e-mail: [fernando.rodriguez@fundacionimabis.org](mailto:fernando.rodriguez@fundacionimabis.org)

**Abstract**

**Rationale** Glutaminase is considered the main Glutamate (Glu) producing enzyme. Two isoforms, liver (LGA) and kidney (KGA) type glutaminases have been identified in neurons. The role of both enzymes in psychopharmacological responses to cocaine remains unknown.

**Objectives** We examined both, mRNA and protein expression of KGA and LGA in the brain of mice sensitized to cocaine. Additionally, total glutaminase activity was also measured.

**Methods** Total glutaminase activity and mRNA and protein expression of KGA and LGA were measured on the dorsal striatum, prefrontal cortex, hippocampus and cerebellum of cocaine-sensitized mice

**Results** Cocaine-sensitized animals (20 mg/kg x 5 days, followed of 5 drug-free days) exhibited a decrease of total glutaminase activity in both the dorsal striatum and the prefrontal cortex. This was associated with an increase in KGA mRNA expression in both brain areas, that was not observed when protein KGA levels were measured by western blot. LGA mRNA expression was increased as results of acute cocaine administration in sensitized animals, although protein levels were only enhanced in the prefrontal cortex of sensitized mice. These findings suggest that chronic cocaine administration modulates glutamate production through the regulation of glutaminase expression and activity. These actions are mainly observed in the prefrontal cortex-dorsal striatum circuit, the neuroanatomical target for the psychostimulant sensitization properties of cocaine.

**Conclusions** The present results indicates that glutaminase enzymes (mainly KGA) are modulated by cocaine in both, the prefrontal cortex and the dorsal striatum, as part of the neuroadaptions associated with behavioural sensitization to this drug of abuse.

**Keywords:** cocaine, glutamate, glutaminase, mice, sensitization, striatum, prefrontal cortex

**Abbreviations**

|        |   |
|--------|---|
| BS     | behavioral sensitization                        |
| CL     | conditioned locomotion                          |
| EAAC1  | neuronal excitatory amino-acid carrier 1        |
| GA     | phosphate-activated glutaminase                 |
| Gln    | glutamine                                       |
| Glu    | glutamate                                       |
| KGA    | kidney-type glutaminase isoform                 |
| LGA    | liver-type glutaminase isoform                  |
| mGluR  | metabotropic glutamate receptor                 |
| NAc    | accumbens nucleus                               |
| PFC    | prefrontal cortex                               |
| RT-PCR | reverse transcription-polymerase chain reaction |
| VTA    | ventral tegmental area                          |

## Introduction

Cocaine, can induce long-term adaptive changes in brain circuits involved in the control of motivated behaviour. Repeated exposure to cocaine and amphetamines induced behavioural sensitization as part of the neuroplasticity changes derived of repeated exposure to these psychostimulants. Modification on both dopamine and glutamate signalling mediate these changes, as it has been described in recent years (Ferrario et al., 2010; Ito et al., 2002; Kalivas, 2004; Mohn et al. 2004). Repeated exposure to psychostimulants produces alterations in glutamatergic transmission within the mesolimbic dopaminergic reward system and associated limbic regions (Kauer and Malenka 2007). Recent studies have implicated glutamatergic synapses in the prefrontal cortex and the dorsal striatum as the place where dynamic changes on glutamate signalling underlies behavioural sensitization. These changes involve both, ionotropic and metabotropic glutamate receptors (Engblom et al. 2008; Ghasemzadeh et al., 2009a and 2009b; Kim et al., 2009). Despite the clear role for glutamate receptors in behavioural sensitization, there is scarce information on the role of biosynthetic enzymes responsible for Glu production (efferent presynaptic terminal) and Glu transport (Miguens et al., 2008) in the glutamatergic excitatory synapses of cocaine sensitized mice.

Glutamate (Glu) is the main excitatory neurotransmitter in the mammalian central nervous system (Collingridge and Lester 1989; Fonnum 1984), whereas glutamine (Gln) is considered an important precursor for its synthesis in brain through phosphate-activated glutaminase (GA) reaction (Kvamme 1984; Nicklas et al. 1987). GA is both an important contributor to transmitter pools of Glu (Nicklas et al. 1987) and the main Gln-utilizing enzyme in neurons (Kvamme 1984). For this reason, GA is regarded as the main glutamate-producer enzyme in the brain. Recently novel GA isoforms have been discovered in the brain of mammals, named as kidney-type glutaminase (KGA) and liver-type glutaminase (LGA), located in the mitochondria and neuronal nuclei respectively (Olalla et al. 2002). The identification of the function of each isozyme is essential for understanding the role of GAs in cerebral function. Some of the physiological functions of GA include synthesis of cerebral Glu, renal ammoniogenesis, nitrogen supply for hepatic urea biosynthesis, and energy supply for the bioenergetics of cells (Curthoys and Watford 1995; Kovacevic and McGivan 1983). In addition to those functions, Glu biosynthesis in the brain regulate synaptogenesis, synaptic plasticity, and participate in the pathogenesis of neuropsychiatric diseases (Conti and Weinberg 1999).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Glu is the precursor for the synthesis of aminobutyric acid (GABA) (Erecinska and Silver 1990). Our group have described the simultaneous expression of LGA and KGA mRNA transcripts in human brain (Aledo et al. 2000; Gomez-Fabre et al. 2000). The regional distribution of GA transcripts indicates that both isoforms co-localize in numerous cells throughout different brain regions (Olalla et al. 2002). Interestingly, LGA isoenzyme was not only expressed in neuronal cells, but also was found in astrocytes (Olalla et al. 2008). Furthermore, co-expression of KGA and LGA isoforms was also demonstrated in brain of other mammalian species like cow, mouse, rabbit, mouse and rat (Olalla et al. 2002). Various regions specifically involved in glutamatergic transmission, such as the cerebral cortex, hippocampus, striatum and cerebellum, were emphasized as those presenting the more intense GA immunolabeling (Marquez et al. 2006).

Understanding the mechanisms by which Glu plays its role in diverse processes requires not only a detailed analysis of the enzymes implicated in Glu synthesis on the presynaptic terminal, but also knowledge of the involved postsynaptic mechanisms. Neuronal excitatory amino acid carrier 1 (EAAC1, also called EAAT3 or SLC1A1) is a transporter capable of uptake extracellular Glu in cerebral cortex, hippocampus, cerebellum, thalamic nuclei, olfactory bulb and spinal cord (Kanai et al. 1995; Kanai and Hediger 1992; Shashidharan et al. 1994). In addition to transporting Glu, EAAC1 is involved in the neuronal uptake of cysteine for the synthesis and maintaining of glutathione homeostasis (Aoyama et al. 2006), and plays other roles in regulating GABA synthesis and supporting neuron viability. It is possible that EAAC1 may have alternative activities distinct from Glu removal because these functions are mainly carried out by transporters of the GLT1 and GLAST subtypes. *Early in situ hybridization* and immunocytochemical studies have shown different patterns of cellular distribution for GLT1, GLAST and EAAC1 (Kanai et al. 1995; Kanai and Hediger 1992; Lehre et al. 1995; Rothstein et al. 1994; Velaz-Faircloth et al. 1996). Comparing these studies can observe that GLT1 and GLAST are mostly located in glial cells, whereas EAAC1 is often expressed in neurons and we chose it for this reason. At the excitatory synapse, EAAC1 could contribute to limit diffusion of Glu from the synapse to extra-synaptic NMDA receptors, avoiding excessive activation of these receptors that could be deleterious in the case of over-stimulation (Nieoullon et al. 2006).

Neither the mRNA expression of glutaminase nor the mRNA expression of the EAAC1 transporter have been studied in the brain of cocaine-sensitized mice. In the present

1  
2  
3 work, we have studied whether the expression of both isoforms of GA and the EAAC1  
4 transporter, as well as total GA activity may be modulated by cocaine in several brain  
5 areas of cocaine-sensitized mice. The results indicate that GA is modulated by cocaine  
6 in the prefrontal cortex-dorsal /dorsal striatum circuit as part of the neuroadaptions  
7 associated with psychostimulant-induced behavioural sensitization.  
8  
9

## 10 11 12 13 **Material and methods**

### 14 15 **Animals and housing**

16 We used male C57BL/6J mice (25±5 g; Charles Rivers Laboratories) for cocaine  
17 behavioural studies, genomic, proteomic and GA enzymatic activity. All animals were  
18 maintained at the central vivarium of the University of Malaga. They were housed in  
19 clear plastic cages and maintained in a temperature (20±2°C) and humidity (40±5%)  
20 controlled room on a 12-h light/dark cycle with food and water *ad libitum*. Moreover,  
21 all mice were handled for 5 min/day for at least 2 days prior to behavioural testing to  
22 reduce the effects on test behavior of the nonspecific stress of being handled. The  
23 maintenance of the animals as well as the experimental procedures were in accordance  
24 with the European animal research laws (European Communities Council Directives  
25 86/609/EU, 98/81/CEE, 2003/65/EC and Commission Recommendation 2007/526/EC).  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 37 **Drug administration**

38 Cocaine-HCl was obtained from Sigma-Aldrich (Madrid, Spain) and dissolved in sterile  
39 0.9% NaCl just before experimentation.  
40  
41  
42

### 43 44 *Acute cocaine dose-response curve*

45 We injected different single-doses (0, 5, 10 and 20 mg/kg) of drug subcutaneously in  
46 C57BL/6J mice (n = 8 per group). After drug administration all animals were tested in  
47 the open field test for 30 minutes through videotracking system (Smart®, Panlab,  
48 Barcelona, Spain) and the total distance travelled (cm) was measured. The open field  
49 used was an opaque square cage with gray arena (40 x 40 x 40 cm) (Panlab, Barcelona,  
50 Spain).  
51  
52  
53  
54  
55  
56

### 57 58 *Cocaine Sensitization*

59 Cocaine sensitization was conducted following a consecutive four-phase paradigm:  
60 cocaine conditioning, drug free period (abstinence), conditioned locomotion (CL) probe  
and behavioural sensitization (BS) test. Firstly, two mice group were injected with  
cocaine (20 mg/kg) or vehicle during five consecutive days and exposed to the open

1  
2  
3 field (cocaine conditioning). Next five days, all animals rested without drug. Then, we  
4 evaluated the locomotor activity response induced by the association between repeated  
5 administrations of cocaine and the place where it exerted its stimulant effect by  
6 simulated administration (vehicle), CL response. Last day, we tested the presence of  
7 sensitization by lower-dose cocaine (priming: 10 mg/kg) administration and BS test was  
8 assessed. All animals were evaluated in the open field test to measure the distance  
9 travelled (cm) for 30 minutes, except in the drug free period. In this way, we had 4  
10 experimental groups: animals conditioned with cocaine (20mg/kg) and administered  
11 with vehicle (n = 8) or cocaine (10 mg/kg) (n = 8), and animals conditioned with vehicle  
12 (n = 8) and treated with vehicle or cocaine (10mg/kg) (n = 8). These independent groups  
13 of animals (chronic cocaine pretreatment + acute vehicle treatment, chronic cocaine  
14 pretreatment + acute cocaine treatment, chronic vehicle pretreatment + acute vehicle  
15 treatment, chronic vehicle pretreatment + acute cocaine treatment) were employed by  
16 gene, protein and enzymatic glutaminase activity studies.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 Analysis of gene expression

31  
32 One hour after acute and chronic cocaine administration, all animals were sacrificed and  
33 their brains removed, frozen (-80° C) and dissected in coronal brain slices (2 mm  
34 thickness) with razor blades in a mouse brain slicer matrix (Zivic Instruments). The  
35 discrete brain regions (striatum, hippocampus, prefrontal cortex and cerebellum) were  
36 picked up by free hand dissection using a scalpel. These brain regions were identified  
37 according to Mouse Brain in Stereotaxic Coordinates (Paxinos and Franklin 2001):  
38 prefrontal cortex from the bregma 2.46 to 1.34 mm, hippocampus from the bregma -  
39 1.22 to -3.52 mm, striatum from the bregma 1.54 to -0.46 mm, and cerebellum from the  
40 bregma -5.52 to -7.80 mm.  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 *Reverse transcription and real-time PCR*

51  
52 Real-time PCR was used to measure relative quantification of synthesis enzymes and  
53 transporter mRNA expression involved in the glutamatergic (LGA and KGA synthesis  
54 enzymes; EAAC1 transporter) neurotransmission. Total RNA from selected brain  
55 regions was isolated using Trizol reagent (Gibco BRL Life Technologies, Baltimore,  
56 MD, USA) according to the manufacturer's instructions, and purified using RNeasy  
57 Mini Kit (Qiagen, Hilden, Germany). RNA concentration and purity were determined  
58 by measuring optical density at 260 nm and 280 nm using a spectrophotometer (Biotech  
59 Photometer, UV 1101, WPA). In all cases, RNA samples showed A260/280 ratios  
60 between 1.8 and 2.0. Reverse transcription and first-strand synthesis from each sample

1  
2  
3 was carried out using random hexamer primers and M-MuLV reverse transcriptase  
4 (Roche Applied Science, Indianapolis, USA) according to manufacturer's instructions.  
5  
6 Negative controls (omitting reverse transcriptase) were run in parallel. Resulting  
7  
8 cDNAs were used as templates for quantitative real-time PCR with an iCycler system  
9  
10 (Bio-Rad, Hercules, CA, USA) using the Quanti-Tect SYBR Green PCR kit (Qiagen,  
11  
12 Hilden, Germany). The following primers were used for real-time PCR (accession no.  
13  
14 from NCBI database): LGA (NM\_001033264) forward: 5'-gcactcggatcatgacgcctcac-3',  
15  
16 reverse: 5'-ttgaccatgcgctgcatcttg-3' (190 bp product); KGA (NM\_001081081)  
17  
18 forward: 5'-gcgagggcaaggagatggtg-3', reverse: 5'-ctctttcaacctgggatcagatgttc-3' (190 bp  
19  
20 product); EAAC1 (BC065099.1) forward: 5'-caggctttctattggcagga-3', reverse: 5'-  
21  
22 acctttccctcccctaaa-3' (216 bp product). Oligonucleotides were provided by Sigma-  
23  
24 Proligo (Proligo France SAS, Paris, France).

25  
26 Quantification was carried out according to standard curves run simultaneously as the  
27  
28 samples with each reaction run in duplicate. The PCR product was separated by  
29  
30 electrophoresis in a 1% agarose gel to verify fragment size and the absence of  
31  
32 contaminant fragments, quantified by measuring the absorbance at 260 nm, and serially  
33  
34 diluted to 10<sup>-5</sup> pg/ml. Several 10-fold dilutions (10<sup>-1</sup> to 10<sup>-5</sup>) were checked for optimal  
35  
36 cycling on the iCycler system (Bio-Rad, Hercules, CA, USA) and three of them were  
37  
38 selected for standard curves. Each reaction was run in duplicate and contained 2,5 µl of  
39  
40 cDNA template, 8 µl of Master SYBR Green, 4,86 µl of PCR Ultra Pure Water and 0,64  
41  
42 µl of primers in a final reaction volume of 15 µl. Cycling parameters were 95°C for 15  
43  
44 min to activate DNA polymerase, then 30-40 cycles of 94°C for 15 s, annealing  
45  
46 temperature for 30 s (LGA: 55°C, KGA: 60°C, EAAC1: 51,4°C and β-actin: 57,1°C) and  
47  
48 a final extension step of 72°C for 30 s in which fluorescence was acquired. Melting  
49  
50 curves analysis was performed to ensure that only a single product was amplified.  
51  
52 Absolute values from each sample were normalised with regard to β-actin (constitutive  
53  
54 gene) mRNA used as reference standard. This internal standard was chosen based on a  
55  
56 first analysis of a panel of housekeeping genes that additionally included cyclophyllin  
57  
58 and SP1.

### 57 *Western blotting*

59 To measure the levels of GA proteins in each brain region, western blotting with  
60 purified specific polyclonal antibodies against KGA or LGA, obtained as described by  
Olalla et al. (2002), were performed. Protein samples (40 µg) were separated on SDS-  
PAGE gels and transferred to nitrocellulose membranes. After blocking at room

1  
2  
3 temperature for 1 h with 5% BSA in TBST buffer (0.1% Tween 20 in TBS), membranes  
4 were incubated with primary antibodies in blocking buffer with 5% BSA, overnight at  
5  
6 4°C. After incubation with secondary antibody, the blots were developed by enhanced  
7  
8 chemiluminescence technique as recommended by the supplier (Pierce) and bands  
9  
10 quantified using the Chemi Doc System (BioRad).  $\beta$ -actin was quantified and used as a  
11  
12 loading control.

### 13 14 15 *GA enzymatic activity*

16 The discrete brain regions from dissections were resuspended in TES buffer (25  
17 mM Tris-HCl, 0.2 mM EDTA, 0.33 M sucrose, pH 8.0) containing the complete  
18  
19 protease inhibitor cocktail (Roche), homogenized and solubilised with TX-100 at a final  
20  
21 concentration of 1% (V/V). After centrifugation at 100000 x g for 30 min at 4 °C, the  
22  
23 supernatants were divided into aliquots and kept at -80 °C until analysis. The protein  
24  
25 content in each sample was determined by the Bradford method. Glutaminase activity  
26  
27 was assayed by measuring the ammonia produced in the catalytic reaction as described  
28  
29 by Heini (1987). Samples of 25  $\mu$ L were added to 35  $\mu$ L of a mixture of 100 mM  
30  
31 potassium phosphate, 171 mM L-glutamine and 1.5 mM  $\text{NH}_4\text{Cl}$ , pH 8.0, and incubated  
32  
33 for 1 h at 37 °C. The reaction was terminated by adding 10  $\mu$ L of TCA 10 %, kept on ice  
34  
35 for 15 min and centrifuged at 12000 x g. Aliquots of 5  $\mu$ L were then mixed with 150  $\mu$ L  
36  
37 of *o*-phthalaldehyde/mercaptoethanol reagent (10 mL 0.2 M potassium phosphate, pH  
38  
39 7.4, 0.56 mL of 72 mM mercaptoethanol in ethanol and 0.56 mL of 186 mM *o*-  
40  
41 phthalaldehyde in ethanol). The samples were kept at room temperature in the dark and  
42  
43 their absorbance measured at 410 nm after 45 min together with a  $\text{NH}_4\text{Cl}$  standard. For  
44  
45 blanks, samples and substrate solution were incubated separately and mixed after the  
46  
47 addition of TCA.

### 48 49 Statistical analysis

50 Results are expressed as the mean  $\pm$  SEM (Standard Error of the Mean) of at least ten  
51  
52 determinations per experimental group. Statistical significance of behavioral results was  
53  
54 assessed by One-way/RM (repeated measured) ANOVA and *post hoc* Newman-Keuls  
55  
56 test. Statistical significance of gene quantifications was analyzed by two-way ANOVA  
57  
58 and *post hoc* Bonferroni test, with acute treatment (vehicle or cocaine for 1 day) and  
59  
60 chronic pretreatment (conditioning with vehicle or cocaine for 5 days) as two main  
factors. In all cases, we considered a statistically significant difference from chance at  
 $p < 0.05$ . All data were analyzed with statistical software SPSS for Windows 11.5 (Lead  
Technologies).

## Results

### *Acute cocaine dose-response effect in C57BL/6J mice*

We measured acute cocaine dose-response curve with different doses (0, 5, 10 and 20 mg/kg) in C57BL/6J mice (see Figure 1.A.). Our results showed a typical progressive enhancement on the distance travelled as cocaine doses were gradually higher (One-way ANOVA, doses effect: ( $F(3,44)=27.0265, p=0.000$ ), with 10 (Tukey. 10 vs. 0,  $p=0.002$ ) and 20 mg/kg dose producing the highest effect (Tukey. 20 vs. 0,  $p=0.000$ ; 20 vs. 5,  $p=0.000$ ; 20 vs. 10,  $p=0.008$ ).

### *Cocaine Sensitization*

All mice injected with vehicle saline exhibited a standard baseline control, whereas acquisition of conditioned response was progressively increased in cocaine exposed animals (20 mg/kg) for 5 days (One-way RM ANOVA, within-subjects factor: ( $F(4,120)=7.761, p=0.001$ ) (see Figure 1.B.). Cocaine treated group showed a significant increase in locomotor activity compared to control group (One-way RM ANOVA, between-groups factor: ( $F(1,30)=208.21, p=0.001$ ) caused by repeated drug injections, every day during treatment (post hoc Newman-Keuls: days 1, 2, 3, 4 and 5;  $p\leq 0.001$ ).

Five days after cocaine conditioning, all groups were subjected to the cocaine CL test with vehicle administration. In this form, chronic cocaine-conditioned group showed a CL response compared to non-conditioned control group (One-way ANOVA, chronic pretreatment effect: ( $F(1,50)=6.5354, p=0.0137$ ) (see Figure 1.C.). This effect was produced by association between the features of environment and cocaine-rewarding properties after 5 consecutive injection-days. One day later, we measured the BS response with animals conditioned with cocaine (20 mg/kg) and administered with vehicle or cocaine (10 mg/kg), and animals conditioned with vehicle and treated with vehicle or cocaine (10 mg/kg). Our results revealed that the groups who had received an acute-cocaine dose (10 mg/kg) showed increased locomotor activity compared to their control groups (One-way ANOVA, acute treatment effect respect to vehicle conditioning group: ( $F(1,15)=30.3958, p=0.001$ ; acute treatment effect respect to cocaine conditioning group: ( $F(1,15)=33.1728, p=0.001$ ). Moreover, this increase was significantly higher in mice that had previously been conditioned with cocaine (20 mg/kg) than those had received the first dose (One-way ANOVA, cocaine sensitization effect: ( $F(1,15)=20.9737, p=0.001$ ) as result of cocaine-induced sensitization (see Figure 1.D.). BS was established on these mice as a model of addiction for the gene

1  
2  
3 expression study, and thus identifies the neuroadaptive changes in the expression of  
4 genes associated with the effects of acute/chronic consumption and the induction of  
5 cocaine sensitization.  
6  
7

8  
9 Cocaine may produce changes in glutamatergic transmission that have been associated  
10 with brain alterations in mice after chronic drug administration. The genomic  
11 dysfunctions induced by acute and chronic cocaine administration in the glutamatergic  
12 system were shown studying the expression of genes involved in biosynthesis and  
13 transport of Glu in the mouse brain. We assessed short/long-term mRNA modifications  
14 caused by differences in acute treatment (vehicle or cocaine for 1 day), chronic  
15 pretreatment (conditioning with vehicle or cocaine for 5 days) and its interaction (acute  
16 treatment x chronic pretreatment). To evaluate these factors, we analyzed the expression  
17 profiles of the genes coding for the enzymes of Glu synthesis (LGA, liver-type  
18 glutaminase; KGA, kidney-type glutaminase), and neuronal Glu transporter (EAAC1) in  
19 prefrontal cortex, hippocampus, striatum and cerebellum of treated-mice (dosing  
20 procedures were as described in the before experimental section).  
21  
22

23  
24  
25  
26  
27  
28  
29  
30 Before analyzing the data region to region, the first relevant result found was that the  
31 KGA mRNA expression levels were much higher compared to LGA in the whole brain  
32 from mouse by qPCR using poly(A+)mRNA. The number of copies to KGA was  
33  $46.96 \times 10^4 \pm 9.48 \times 10^4$ , while to LGA was only  $3.021 \times 10^4 \pm 0.33 \times 10^4$  (authors'  
34 unpublished results, manuscript in preparation).  
35  
36  
37  
38  
39  
40  
41

42  
43 *LGA expression is activated by acute-cocaine treatment in the prefrontal cortex and*  
44 *acute-cocaine priming in striatum*

45  
46 We analyzed regional pattern of LGA gene expression after cocaine administration. In  
47 prefrontal cortex, LGA mRNA expression levels showed significant changes in acute  
48 (Two-way ANOVA, acute treatment effect: ( $F(1,27)=4.2880, p=0.0481$ ), but neither  
49 chronic administration (Two-way ANOVA, chronic pretreatment effect: ( $F$   
50 ( $1,27)=3.4110, p=0.0758$ ), nor interaction effect (Two-way ANOVA, acute treatment x  
51 chronic pretreatment effect: ( $F(1,27)=0.0982, p=0.7564$ ) were found (see Figure 2.C.).  
52 In this case, levels of LGA mRNA in acute-cocaine/sensitized mice were increased in  
53 the prefrontal cortex. Otherwise, LGA expression in the striatal region (see Figure 2.A.)  
54 did not show any significant difference when cocaine was injected with acute (Two-way  
55 ANOVA, acute treatment effect: ( $F(1,24)=3.275, p=0.0829$ ) or chronic injection  
56 protocols (Two-way ANOVA, chronic pretreatment effect: ( $F(1,24)=1.399, p=0.2485$ ).  
57 However, we found an interaction effect between both variables (Two-way ANOVA,  
58  
59  
60

1  
2  
3 acute treatment x chronic pretreatment effect: ( $F(1,24)=8.418, p=0.0078$ ) that could  
4 indicates that part of this effect might be due to a robust cocaine-induced neuronal  
5 sensitization. On the other hand, the expression profile of LGA mRNA was similar in  
6 hippocampus and cerebellum (see Figure 2.B-D.). Levels of LGA expression did not  
7 show changes after different treatments, chronic pretreatment (Hippocampus. Two-way  
8 ANOVA, chronic pretreatment effect: ( $F(1,27)=0.5214, p=0.4765$ ; Cerebellum. Two-  
9 way ANOVA, chronic pretreatment effect: ( $F(1,25)=0.1109, p=0.7419$ ) and acute  
10 treatment (Hippocampus. Two-way ANOVA, acute treatment effect: ( $F(1,27)=0.4346,$   
11  $p=0.5153$ ; Cerebellum. Two-way ANOVA, acute treatment effect: ( $F(1,25)=4.185,$   
12  $p=0.0514$ ) with cocaine, nor interaction (Hippocampus. Two-way ANOVA, acute  
13 treatment x chronic pretreatment effect: ( $F(1,27)=0.0246, p=0.8764$ ; Cerebellum. Two-  
14 way ANOVA, acute treatment x chronic pretreatment effect: ( $F(1,25)=0.2993,$   
15  $p=0.5891$ ).

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 *KGA expression is activated by chronic-cocaine pretreatment in striatum but is*  
29 *inhibited by acute-cocaine treatment in hippocampus*

30  
31 In striatal region, the expression of KGA synthesis enzyme showed statistically  
32 significant differences caused by chronic pretreatment (Two-way ANOVA, chronic  
33 pretreatment effect: ( $F(1,27)=5.369, p=0.0283$ ) (see Figure 3.A.). Repeated  
34 administration of cocaine increased KGA expression basal levels in striatum. Chronic  
35 pretreatment produced long-term overstimulation throughout the increased neuronal  
36 excitability of glutamatergic striatal neurons. This neural excitation may be caused by  
37 an enhanced KGA enzymatic activity related to an augmented locomotion induced by  
38 cocaine conditioning. Instead KGA did not show significant differences in acute  
39 treatment (Two-way ANOVA, acute treatment effect: ( $F(1,27)=0.0251, p=0.8751$ ) or  
40 interaction (Two-way ANOVA, acute treatment x chronic pretreatment effect: ( $F$   
41 ( $1,27)=3.273, p=0.0816$ ). In the other way, our data show that acute treatment  
42 diminished KGA expression basal levels in hippocampus (Two-way ANOVA, acute  
43 treatment effect: ( $F(1,27)=15.840, p=0.0005$ ), but we did not find differences produced  
44 by chronic pretreatment (Two-way ANOVA, chronic pretreatment effect: ( $F$   
45 ( $1,27)=1.980, p=0.1708$ ) or interaction (Two-way ANOVA, acute treatment x chronic  
46 pretreatment effect: ( $F(1,27)=1.980, p=0.1708$ ) (see Figure 3.B.). These results suggest  
47 that, under acute conditions, cocaine may downregulate the transcription of KGA.  
48 Moreover, the measurement of KGA expression in prefrontal cortex and cerebellum did  
49 not show variations induced by chronic pretreatment (Prefrontal cortex. Two-way  
50 ANOVA, chronic pretreatment effect: ( $F(1,24)=2.384, p=0.1357$ ; Cerebellum. Two-  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 way ANOVA, chronic pretreatment effect: ( $F(1,26)=3.303, p=0.0807$ ), acute treatment  
4 (Prefrontal cortex. Two-way ANOVA, acute treatment effect: ( $F(1,24)=3.432,$   
5  $p=0.0763$ ; Cerebellum. Two-way ANOVA, acute treatment effect: ( $F(1,26)=1.107,$   
6  $p=0.3024$ ), or interaction (Prefrontal cortex. Two-way ANOVA, acute treatment x  
7 chronic pretreatment effect: ( $F(1,24)=0.678, p=0.1484$ ; Cerebellum. Two-way  
8 ANOVA, acute treatment x chronic pretreatment effect: ( $F(1,26)=1.626, p=0.2135$ )  
9 (see Figure 3.C-D.).

16  
17 *EAAC1 glutamate transporter expression is decreased in striatum after both acute- and*  
18 *chronic-cocaine treatments but increased in cerebellum by chronic pretreatment*

20 Regarding the EAAC1 Glu transporter in striatum, our data showed statistically  
21 significant differences in both forms of cocaine administration. The levels of EAAC1  
22 transporter in striatum were affected by cocaine acute treatment (Two-way ANOVA,  
23 acute treatment effect: ( $F(1,24)=13.610, p=0.001$ ) and chronic pretreatment (Two-way  
24 ANOVA, chronic pretreatment effect: ( $F(1,24)=8.386, p=0.008$ ), but not their  
25 interaction (Two-way ANOVA, acute treatment x chronic pretreatment effect: ( $F$   
26 ( $1,24)=1.548, p=0.225$ ) (see Figure 4.A.). This means that cocaine conditioning as well  
27 as the acute treatment and relapse to the drug diminished the levels of EAAC1  
28 transporter mRNA expression in striatum. In case of the EAAC1 mRNA expression  
29 levels in cerebellum, we observed a chronic effect induced by cocaine pretreatment  
30 (Two-way ANOVA, chronic pretreatment effect: ( $F(1,27)=4.520, p=0.043$ ), but not by  
31 acute treatment (Two-way ANOVA, acute treatment effect: ( $F(1,27)=0.322, p=0.575$ )  
32 or interaction (Two-way ANOVA, acute treatment x chronic pretreatment effect: ( $F$   
33 ( $1,27)=1.034, p=0.318$ ) (see Figure 4.C.). This enhancement in the levels of Glu  
34 transporter mRNA could be due to initial chronic pretreatment with cocaine in  
35 Purkinje's cells where EAAC1 transporter is especially abundant. The remaining regions  
36 studied, hippocampus and prefrontal cortex, did not present differences in the rest of  
37 comparisons for Glu transporter (see Figure 4.B-D.). Levels of EAAC1 expression did  
38 not show modifications after diverse treatments, chronic pretreatment (Hippocampus.  
39 Two-way ANOVA, chronic pretreatment effect: ( $F(1,27)=1.655, p=0.209$ ; Prefrontal  
40 cortex. Two-way ANOVA, chronic pretreatment effect: ( $F(1,26)=3.276, p=0.082$ ) and  
41 acute treatment (Hippocampus. Two-way ANOVA, acute treatment effect: ( $F$   
42 ( $1,27)=1.212, p=0.281$ ; Prefrontal cortex. Two-way ANOVA, acute treatment effect: ( $F$   
43 ( $1,26)=0.138, p=0.713$ ) with cocaine, nor interaction (Hippocampus. Two-way  
44 ANOVA, acute treatment x chronic pretreatment effect: ( $F(1,27)=3.400, p=0.076$ ;

1  
2 Prefrontal cortex. Two-way ANOVA, acute treatment x chronic pretreatment effect: ( $F$   
3 ( $1,26$ )= $1.483$ ,  $p=0.234$ ).  
4  
5  
6

#### 7 *Western blotting results*

8  
9 After ending the analysis of genomic changes, LGA and KGA protein levels were  
10 measured on brain regions in where had been revealed changes in mRNA glutaminase  
11 expression (see Figure 5.A-D), by western blotting. In this sense, we only observed a  
12 significant interaction effect between acute x chronic cocaine pretreatment (Two way  
13 ANOVA: Interaction effect  $F(1,20)=12.80$ ,  $p<0.01$ ) in LGA protein levels measured in  
14 Prefrontal Cortex (see Figure 5.B.).  
15  
16  
17  
18  
19  
20  
21

#### 22 *GA activity results*

23  
24 Our results showed a reduced GA activity in Striatum (Two way ANOVA: Pre-  
25 treatment effect  $F(1,20)=7.787$ ,  $p<0.05$ ) and Prefrontal Cortex (Two way ANOVA: Pre-  
26 treatment effect  $F(1,20)=26.17$ ,  $p<0.001$ ) after chronic cocaine pretreatment, but this  
27 effect did not found in Hippocampus (Two way ANOVA: Pre-treatment effect  $F(1,20)=$   
28  $0.8354$ ,  $p<0.3716$ ) after cocaine conditioning (see Figure 6.A-C). This functional  
29 measured did not show significant differences after acute treatment in the brain regions  
30 evaluated (Striatum, Two way ANOVA: Treatment effect  $F(1,20)=0.01884$ ,  $p<0.8922$ ;  
31 Hippocampus, Two way ANOVA: Pre-treatment effect  $F(1,20)=0.8354$ ,  $p<0.3716$ ;  
32 Prefrontal Cortex, Two way ANOVA: Treatment effect  $F(1,20)=1.947$ ,  $p<0.1782$ ) (see  
33 Figure 6.A-C). In summary, we observed a reduction of enzymatic GA activity in the  
34 striatum and prefrontal cortex after 5 days of abstinence.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

Three main findings arise from the present studies. First, glutaminase (GA) activity is decreased after repeated exposure to cocaine, using a dose regimen that induces behavioural sensitization to this psychostimulant. Second, there is a clear temporal dissociation between the effects on the expression of the mRNAs for GA isoforms and the EAAC1 glutamate transporter, which are mainly affected after acute cocaine challenge, and the total GA activity, which is affected mainly by repeated exposure to the psychostimulant. Third, main changes were observed on the prefrontal cortex-dorsal striatum circuit, which are the anatomical site for the neuroplasticity events that underlie cocaine-induced behavioural sensitization (Dong et al., 2005; Engblom et al. 2008; Everitt and Wolf, 2002; Ghasemzadeh et al., 2009a; Kim et al., 2009). Overall, the results set in place GA as a relevant protein involved in the neuroadaptions associated to repeated cocaine exposure.

Glutaminase activity changes can be attributed to alterations on KGA since in the mouse brain there is a differential expression of L- and K-type GA isoforms. The presence of KGA is much higher than LGA in the whole mouse brain measured by qPCR using poly(A+)mRNA (authors' unpublished results, manuscript in preparation). In general terms, KGA biosynthetic enzyme expression is much more abundant than LGA in prefrontal cortex, hippocampus, striatum and cerebellum. These data are consistent with our previous results at the protein level, showing that KGA immunolabeling was more pronounced in the mammalian brain than LGA (Olalla et al. 2002; Olalla et al. 2008). This differential pattern of expression could be due to the fact that KGA was located in the mitochondrial compartment while LGA was mostly found in the neuronal nuclei (Olalla et al. 2002). Glutaminase activity was not affected by acute cocaine challenge neither in vehicle-exposed nor in cocaine-exposed animals. However, two-way ANOVA revealed that repeated cocaine exposure elicited a decrease in GA activity in both, the dorsal striatum and the prefrontal cortex. Neither a vehicle injection nor a challenge with a cocaine injection was able to recover the GA activity values to those shown by acute-control or acute-cocaine treated animals. Cocaine-induced sensitization is associated to enhanced glutamate transmission in both brain areas (Nasif et al., 2005a and 2005b). This action of cocaine is produced by dynamic changes in both glutamate release (Pierce et al., 1996; McFarland et al, 2003) and glutamate receptor signalling ((Engblom et al. 2008; Ghasemzadeh et al., 2009a; Kim et al., 2009; Xi et al., 2002; Xi and steketee, 2008). In this context, the decrease in GA activity may be either a counter-regulatory inhibition to compensate the enhanced

1  
2  
3 glutamate output or be related to the fact that withdrawal from repeated exposure to  
4 cocaine reduces basal extracellular Glu levels in the basal ganglia (Schmidt and Pierce,  
5 2010). Since we observed enhanced GA activity 5 days after cessation of repeated  
6 cocaine exposure, this explanation seems to be plausible.  
7  
8

9  
10 The second relevant finding is the confirmation of the modification of the expression  
11 GA isoforms expression as result of cocaine administration. Cocaine has been shown to  
12 alter Glu transmission in ventral tegmental area (VTA) and its projection areas, both  
13 directly to the accumbens nucleus (NAc) or indirectly (substantia nigra, medial  
14 prefrontal cortex, septo-hippocampal area, cerebellum) contributing in the  
15 psychostimulant behavioral effects (Kalivas 2004; Kalivas et al. 2009). But the role of  
16 GA enzymes and EAAC1 transport on the mediation of cocaine-induced sensitization  
17 was unknown in these brain regions. This is a relevant issue since the prefrontal-  
18 cortex/dorsal striatum circuit is the key anatomical target for chronic cocaine actions.  
19 Understanding glutamate dynamics in this circuit may help us to understand the  
20 vulnerability to develop compulsive drug-seeking habits in cocaine addiction (Everitt et  
21 al. 2008). In the dorsal striatum, we observed an increased expression of the mRNAs  
22 coding for KGA and LGA after acute cocaine exposure in cocaine sensitized animals,  
23 which contrasts with the decrease in the activity observed in these areas. This indicates  
24 that cocaine exposure dissociates the up-regulation of GA mRNA isoforms from protein  
25 activity. This finding stresses the importance of monitoring not only mRNA expression  
26 but protein levels and activity, since cell phenotype is derived from the later (Pradet-  
27 Balade et al., 2001). Similar dissociations have been described for glutamate receptors  
28 in VTA of cocaine exposed-animals (Choi et al., 2011).  
29  
30

31  
32 The decrease in the expression of the EAAC1 carrier after acute cocaine, in both control  
33 and cocaine-sensitized animals, suggest that this Glu transporter plays also a role in the  
34 neuroadaptions to cocaine. Although we do not have functional evaluation of its  
35 activity, previous results support this idea. Thus, the decrease in basal accumbal Glu  
36 during withdrawal from chronic cocaine exposure has been attributed to a cocaine-  
37 modulation of the activity of the cysteine-Glu antiporter (Baker DA et al., 2002 and  
38 2003).  
39  
40  
41  
42

43  
44 Finally, major changes were observed in the prefrontal cortex-dorsal striatum circuit, in  
45 agreement with the described role for these brain areas in psychostimulant-induced  
46 sensitization. Outside from this circuit, our data indicated that neither GA activity nor  
47 LGA and EAAC1 mRNA levels were unaffected in mouse hippocampus or cerebellum,  
48 with the exception of a small increase in cerebellar expression of the transporter as  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 result of cocaine challenge. The only robust effect observed after cocaine exposure  
4 outside the cortico-striatal circuit was a decrease in KGA expression in the  
5 hippocampus after acute cocaine in both control and cocaine-sensitized animals. This  
6 decrease in KGA expression has an impact neither in protein levels nor in total GA  
7 activity. This pattern of restricted regional effects of cocaine has been found also in  
8 other members of the Glutamate signalling pathway such as the mGluR8 whose protein  
9 expression levels in the hippocampus and prefrontal cortex also remained constant after  
10 acute cocaine injection while they were down-regulated in the striatum (Zhang et al.  
11 2009).

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 In summary, our data suggest that cocaine sensitization is associated to prefrontal  
23 cortex-dorsal striatum decrease in the activity of Glu synthetic enzymes, and to a  
24 modulation of the expression of GA isoforms and the EAAC1 Glu transporter. Minor  
25 changes were observed in the hippocampus and cerebellum indicating than in this  
26 model of cocaine actions the main relevant target is the dorsal striatum and functionally  
27 associated PFC. These observed changes in the levels of Glu biosynthetic activity and  
28 transporter may alter excitatory neurotransmission in the mesocorticolimbic dopamine  
29 system, which could play a significant role in the enduring biochemical and behavioural  
30 effects of cocaine. Further research is needed to understand the temporal dynamics of  
31 GA contribution to cocaine-induced behavioural sensitization.

### 32 33 34 35 36 37 38 39 40 41 **Acknowledgments**

42  
43 This work was supported by grants of excellence (P07-CTS-03324) (to F.R.F) and CVI-  
44 1543 (to J.M.) from the Consejería de Innovación, Ciencia y Empresa of the Regional  
45 Andalusian Government, grants RD06/1001 (to F.R.F.) and RD06/1012 (to J.M.) of the  
46 RTA RETICS network from the Spanish Health Institute Carlos III, grant SAF2007-  
47 61953 from the Spanish Ministry of Education and Science (to J.M.) and grant  
48 G29830643 from the Plan Nacional sobre Drogas 2009-2011 (to F.R.F.). E. Blanco is a  
49 recipient of a postdoctoral fellowship (Juan de la Cierva, 2008) from the Spanish  
50 Ministry of Education and Science. J.A. Campos-Sandoval is a recipient of a Marie  
51 Curie Post Doctoral Fellowship from the European Union.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1  
2  
3  
4 Aledo JC, Gomez-Fabre PM, Olalla L, Marquez J (2000) Identification of two human  
5 glutaminase loci and tissue-specific expression of the two related genes. *Mamm*  
6 *Genome* 11: 1107-10  
7  
8 Aoyama K, Suh SW, Hamby AM, Liu J, Chan WY, Chen Y, Swanson RA (2006)  
9 Neuronal glutathione deficiency and age-dependent neurodegeneration in the  
10 EAAC1 deficient mouse. *Nat Neurosci* 9: 119-26  
11  
12 Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, Kalivas PW. (2003)  
13 Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. *Nat*  
14 *Neurosci* 67:743-9.  
15  
16 Baker DA, Shen H, Kalivas PW. (2002) Cystine/glutamate exchange serves as the  
17 source for extracellular glutamate: modifications by repeated cocaine  
18 administration. *Amino Acids*. 23:161-2.  
19  
20 Choi KH, Edwards S, Graham DL, Larson EB, Whisler KN, Simmons D, Friedman  
21 AK, Walsh JJ, Rahman Z, Monteggia LM, Eisch AJ, Neve RL, Nestler EJ, Han  
22 MH, Self DW. (2011) Reinforcement-related regulation of AMPA glutamate  
23 receptor subunits in the ventral tegmental area enhances motivation for cocaine.  
24 *J Neurosci*. 2011 May 25;31(21):7927-37.  
25  
26 Collingridge GL, Lester RA (1989) Excitatory amino acid receptors in the vertebrate  
27 central nervous system. *Pharmacol Rev* 41: 143-210  
28  
29 Conti F, Weinberg RJ (1999) Shaping excitation at glutamatergic synapses. *Trends*  
30 *Neurosci* 22: 451-8  
31  
32 Curthoys NP, Watford M (1995) Regulation of glutaminase activity and glutamine  
33 metabolism. *Annu Rev Nutr* 15: 133-59  
34  
35 Dong Y, Nasif FJ, Tsui JJ, Ju WY, Cooper DC, Hu XT, Malenka RC, White FJ (2005)  
36 Cocaine-induced plasticity of intrinsic membrane properties in prefrontal cortex  
37 pyramidal neurons: adaptations in potassium currents. *J Neurosci* 25: 936-40  
38  
39 Engblom D, Bilbao A, Sanchis-Segura C, Dahan L, Perreau-Lenz S, Balland B,  
40 Parkitna JR, Lujan R, Halbout B, Mameli M, Parlato R, Sprengel R, Luscher C,  
41 Schutz G, Spanagel R (2008) Glutamate receptors on dopamine neurons control  
42 the persistence of cocaine seeking. *Neuron* 59: 497-508  
43  
44 Erecinska M, Silver IA (1990) Metabolism and role of glutamate in mammalian brain.  
45 *Prog Neurobiol* 35: 245-96  
46  
47 Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW (2008)  
48 Review. Neural mechanisms underlying the vulnerability to develop compulsive  
49 drug-seeking habits and addiction. *Philos Trans R Soc Lond B Biol Sci* 363:  
50 3125-35  
51  
52 Everitt BJ, Wolf ME (2002) Psychomotor stimulant addiction: a neural systems  
53 perspective. *J Neurosci* 22: 3312-20  
54  
55 Ferrario CR, Li X, Wang X, Reimers JM, Uejima JL, Wolf ME. (2010) The role of  
56 glutamate receptor redistribution in locomotor sensitization to cocaine.  
57 *Neuropsychopharmacology*. 35:818-33.  
58  
59 Fonnum F (1984) Glutamate: a neurotransmitter in mammalian brain. *J Neurochem* 42:  
60 1-11  
61  
62 Ghasemzadeh MB, Mueller C, Vasudevan P (2009a) Behavioral sensitization to cocaine  
63 is associated with increased glutamate receptor trafficking to the postsynaptic  
64 density after extended withdrawal period. *Neuroscience* 159: 414-26  
65  
66 Ghasemzadeh MB, Vasudevan P, Mueller C, Seubert C, Mantsch JR (2009b)  
67 Neuroadaptations in the cellular and postsynaptic group 1 metabotropic  
68 glutamate receptor mGluR5 and Homer proteins following extinction of cocaine  
69 self-administration. *Neurosci Lett* 452: 167-71

- 1  
2  
3 Gomez-Fabre PM, Aledo JC, Del Castillo-Olivares A, Alonso FJ, Nunez De Castro I,  
4 Campos JA, Marquez J (2000) Molecular cloning, sequencing and expression  
5 studies of the human breast cancer cell glutaminase. *Biochem J* 345 Pt 2: 365-75
- 6 Heini HG, Gebhardt R, Brecht A, Mecke D (1987) Purification and characterization of  
7 rat liver glutaminase. *Eur J Biochem* 162: 541-6
- 8 Ito R, Dalley JW, Robbins TW, Everitt BJ (2002) Dopamine release in the dorsal  
9 striatum during cocaine-seeking behavior under the control of a drug-associated  
10 cue. *J Neurosci* 22: 6247-53
- 11 Kalivas PW (2004) Glutamate systems in cocaine addiction. *Curr Opin Pharmacol* 4:  
12 23-9
- 13 Kalivas PW, Lalumiere RT, Knackstedt L, Shen H (2009) Glutamate transmission in  
14 addiction. *Neuropharmacology* 56 Suppl 1: 169-73
- 15 Kanai Y, Bhide PG, DiFiglia M, Hediger MA (1995) Neuronal high-affinity glutamate  
16 transport in the rat central nervous system. *Neuroreport* 6: 2357-62
- 17 Kanai Y, Hediger MA (1992) Primary structure and functional characterization of a  
18 high-affinity glutamate transporter. *Nature* 360: 467-71
- 19 Kauer JA, Malenka RC (2007) Synaptic plasticity and addiction. *Nat Rev Neurosci* 8:  
20 844-58
- 21  
22  
23  
24 **Kim M, Au E, Neve R, Yoon BJ. (2009)AMPA receptor trafficking in the dorsal**  
25 **striatum is critical for behavioral sensitization to cocaine in juvenile mice.**  
26 **Biochem Biophys Res Commun.379:65-9.**
- 27 Kovacevic Z, McGivan JD (1983) Mitochondrial metabolism of glutamine and  
28 glutamate and its physiological significance. *Physiol Rev* 63: 547-605
- 29 Kvamme K (1984) Glutamine Metabolism in Mammalian Tissues. In: Häussinger D,  
30 Sies H (eds) *Enzymes of cerebral glutamine metabolism*. Springer Verlag,  
31 Berlin, pp 32-48
- 32  
33 Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC (1995) Differential  
34 expression of two glial glutamate transporters in the rat brain: quantitative and  
35 immunocytochemical observations. *J Neurosci* 15: 1835-53
- 36 Marquez J, de la Oliva AR, Mates JM, Segura JA, Alonso FJ (2006) Glutaminase: a  
37 multifaceted protein not only involved in generating glutamate. *Neurochem Int*  
38 48: 465-71
- 39  
40 **McFarland K, Lapish CC, Kalivas PW. (2003) Prefrontal glutamate release into the core**  
41 **of the nucleus accumbens mediates cocaine-induced reinstatement of drug-**  
42 **seeking behavior. J Neurosci. 23:3531-7.**
- 43  
44 Miguens M, Crespo JA, Del Olmo N, Higuera-Matas A, Montoya GL, Garcia-  
45 Lecumberri C, Ambrosio E (2008) Differential cocaine-induced modulation of  
46 glutamate and dopamine transporters after contingent and non-contingent  
47 administration. *Neuropharmacology* 55: 771-9
- 48 Mohn AR, Yao WD, Caron MG (2004) Genetic and genomic approaches to reward and  
49 addiction. *Neuropharmacology* 47 Suppl 1: 101-10
- 50 Nasif FJ, Hu XT, White FJ (2005a) Repeated cocaine administration increases voltage-  
51 sensitive calcium currents in response to membrane depolarization in medial  
52 prefrontal cortex pyramidal neurons. *J Neurosci* 25: 3674-9
- 53 Nasif FJ, Sidiropoulou K, Hu XT, White FJ (2005b) Repeated cocaine administration  
54 increases membrane excitability of pyramidal neurons in the rat medial  
55 prefrontal cortex. *J Pharmacol Exp Ther* 312: 1305-13
- 56  
57 Nicklas WJ, Zeevalk G, Hyndman A (1987) Interactions between neurons and glia in  
58 glutamate/glutamine compartmentation. *Biochem Soc Trans* 15: 208-10
- 59 Nieoullon A, Canolle B, Masméjean F, Guillet B, Pisano P, Lortet S (2006) The  
60 neuronal excitatory amino acid transporter EAAC1/EAAT3: does it represent a  
major actor at the brain excitatory synapse? *J Neurochem* 98: 1007-18

- 1  
2  
3 Olalla L, Gutierrez A, Campos JA, Khan ZU, Alonso FJ, Segura JA, Marquez J, Aledo  
4 JC (2002) Nuclear localization of L-type glutaminase in mammalian brain. *J*  
5 *Biol Chem* 277: 38939-44
- 6 Olalla L, Gutierrez A, Jimenez AJ, Lopez-Tellez JF, Khan ZU, Perez J, Alonso FJ, de la  
7 Rosa V, Campos-Sandoval JA, Segura JA, Aledo JC, Marquez J (2008)  
8 Expression of the scaffolding PDZ protein glutaminase-interacting protein in  
9 mammalian brain. *J Neurosci Res* 86: 281-92
- 10 Paxinos G, Franklin KBJ (2001) *The mouse brain in stereotaxic coordinates*, 2nd edn.  
11 Academic, Academic
- 12 **Pierce RC, Bell K, Duffy P, Kalivas PW. (1996) Repeated cocaine augments excitatory**  
13 **amino acid transmission in the nucleus accumbens only in rats having**  
14 **developed behavioral sensitization. *J Neurosci.* 16:1550-60.**
- 15 **Pradet-Balade B, Boulmé F, Beug H, Müllner EW, Garcia-Sanz JA. (2001) Translation**  
16 **control: bridging the gap between genomics and proteomics? *Trends Biochem***  
17 ***Sci.* 26:225-9.**
- 18 Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW  
19 (1994) Localization of neuronal and glial glutamate transporters. *Neuron* 13:  
20 713-25
- 21 Schmidt HD, Pierce RC. (2010) Cocaine-induced neuroadaptations in glutamate  
22 transmission: potential therapeutic targets for craving and addiction. *Ann N Y*  
23 *Acad Sci.* 1187:35-75.
- 24 Shashidharan P, Huntley GW, Meyer T, Morrison JH, Plaitakis A (1994) Neuron-  
25 specific human glutamate transporter: molecular cloning, characterization and  
26 expression in human brain. *Brain Res* 662: 245-50
- 27 Velaz-Faircloth M, McGraw TS, alandro MS, Fremeau RT, Jr., Kilberg MS, Anderson  
28 KJ (1996) Characterization and distribution of the neuronal glutamate  
29 transporter EAAC1 in rat brain. *Am J Physiol* 270: C67-75
- 30 Xi ZX, Ramamoorthy S, Baker DA, Shen H, Samuvel DJ, Kalivas PW (2002)  
31 Modulation of group II metabotropic glutamate receptor signaling by chronic  
32 cocaine. *J Pharmacol Exp Ther* 303: 608-15
- 33 Xie X, Stekete JD (2008) Repeated exposure to cocaine alters the modulation of  
34 mesocorticolimbic glutamate transmission by medial prefrontal cortex Group II  
35 metabotropic glutamate receptors. *J Neurochem* 107: 186-96
- 36 Zhang GC, Vu K, Parelkar NK, Mao LM, Stanford IM, Fibuch EE, Wang JQ (2009)  
37 Acute administration of cocaine reduces metabotropic glutamate receptor 8  
38 protein expression in the rat striatum in vivo. *Neurosci Lett* 449: 224-7
- 39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure Legends

**Fig. 1: A.** Acute cocaine dose-response curve in C57BL/6J mice. Different doses of acute cocaine (0, 5, 10 and 20 mg/kg) showed an increase in total distance travelled in the open-field. The 10-20 mg/Kg doses significantly increased distance travelled compared to other doses. \*\* $p < 0.01$  and \*\*\*  $p < 0.001$  compared to vehicle group, or ##  $p < 0.01$  and ###  $p < 0.001$  compared to cocaine 20 mg/kg group. **B.** Chronic cocaine conditioning. Acquisition of the cocaine conditioned response increased during 5 treatment's days. Cocaine-treated group showed a significant increase in locomotor activity compared to control group by chronic drug-injections. \*\*\*  $p < 0.001$  compared to vehicle group each treatment day. **C.** Conditioned Locomotion (CL) response induced by chronic cocaine administration after a vehicle injection. \*\*  $p < 0.01$  compared to vehicle group. **D.** Behavioral Sensitization (BS) response was measured with animals conditioned with cocaine/vehicle (20mg/kg) and administered with vehicle/cocaine (10 mg/kg) in the probe. Acute-cocaine treated groups (10 mg/kg) showed increased locomotor activity compared with control groups. Between previously cocaine-treated groups, the enhancement was significantly higher in cocaine-conditioned pretreated mice (20mg/kg) than non-conditioned pretreated mice as consequence of cocaine-induced sensitization. \*\*\*  $p < 0.001$  compared to vehicle groups and ###  $p < 0.001$  compared to cocaine 10 mg/kg group. All results are presented as means  $\pm$  SEM (n = at least 8 per group).


**Fig. 2:** Quantitative real-time PCR analysis of liver-type glutaminase (LGA) mRNA expression normalized to the levels of  $\beta$ -actin mRNA in different brain regions. Each value corresponds to mRNA levels in C57BL/6J mice after acute treatment (sensitization with vehicle or cocaine for 1 day) and chronic pretreatment (conditioning with vehicle or cocaine for 5 days). **A.** Comparison of the expression of LGA in the striatum of cocaine acute treated and chronic pretreated mice. **B.** Comparison of the expression of LGA in the hippocampus of cocaine acute treated and chronic pretreated mice. **C.** Comparison of the expression of LGA in the prefrontal cortex of cocaine acute treated and chronic pretreated mice. **D.** Comparison of the expression of LGA in the cerebellum of cocaine acute treated and chronic pretreated mice. Bars indicate the mean value  $\pm$  SEM. Two-way ANOVA followed by Bonferroni post hoc test, \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$  (n = 7-8 per group)..

1  
2  
3 **Fig. 3:** Quantitative real-time PCR analysis of kidney-type glutaminase (KGA) mRNA  
4 expression normalized to the levels of  $\beta$ -actin mRNA in different brain regions. Each  
5 value corresponds to mRNA levels in C57BL/6J mice after acute treatment  
6 (sensitization with vehicle or cocaine for 1 day) and chronic pretreatment (conditioning  
7 with vehicle or cocaine for 5 days). **A.** Comparison of the expression of KGA in the  
8 striatum of cocaine acute treated and chronic pretreated mice. **B.** Comparison of the  
9 expression of KGA in the hippocampus of cocaine acute treated and chronic pretreated  
10 mice. **C.** Comparison of the expression of KGA in the prefrontal cortex of cocaine acute  
11 treated and chronic pretreated mice. **D.** Comparison of the expression of KGA in the  
12 cerebellum of cocaine acute treated and chronic pretreated mice. Bars indicate the mean  
13 value  $\pm$  SEM. Two-way ANOVA followed by Bonferroni post hoc test, \* $p < 0.05$ ;  
14 \*\* $p < 0.01$ ; \*\*\* $p < 0.001$  ( $n = 7-8$  per group).  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 **Fig. 4:** Quantitative real-time PCR analysis of neuronal Glu transporter (EAAC1)  
27 mRNA expression normalized to the levels of  $\beta$ -actin mRNA in different brain regions.  
28 Each value corresponds to mRNA levels in C57BL/6J mice after acute treatment  
29 (sensitization with vehicle or cocaine for 1 day) and chronic pretreatment (conditioning  
30 with vehicle or cocaine for 5 days). **A.** Comparison of the expression of EAAC1 in the  
31 striatum of cocaine acute treated and chronic pretreated mice. **B.** Comparison of the  
32 expression of EAAC1 in the hippocampus of cocaine acute treated and chronic  
33 pretreated mice. **C.** Comparison of the expression of EAAC1 in the prefrontal cortex of  
34 cocaine acute treated and chronic pretreated mice. **D.** Comparison of the expression of  
35 EAAC1 in the cerebellum of cocaine acute treated and chronic pretreated mice. Bars  
36 indicate the mean value  $\pm$  SEM. Two-way ANOVA followed by Bonferroni post hoc  
37 test, \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$  ( $n = 7-8$  per group).  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48


49 **Fig. 5:** Quantitative analysis of LGA protein levels in Striatum (A) ( $n = 5$ ) and  
50 Prefrontal Cortex (B) ( $n = 6$ ), and KGA in Striatum (C) ( $n = 6$ ) and Hippocampus (D) ( $n$   
51  $= 6$ ) after acute treatment vs. chronic pretreatment with vehicle and cocaine in mice by  
52 using western blot analysis. Protein levels were normalized to  $\beta$ -actin as arbitrary units  
53 of optical density (mean  $\pm$  SEM) as arbitrary units of optical density (mean  $\pm$  SEM).  
54  
55  
56  
57 \*\* $p < 0.01$   
58  
59  
60

**Fig. 6:** Quantification of the enzymatic activity to glutaminase in Striatum (A) ( $n = 6$ ),  
Hippocampus (B) ( $n = 6$ ) and Prefrontal Cortex (C) ( $n = 6$ ) after acute treatment vs.  
chronic pretreatment with vehicle and cocaine in mice. \* $p < 0.05$ ; \*\*\* $p < 0.001$ .




77x54mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




47x14mm (600 x 600 DPI)



|                             |    |     |    |    |
|-----------------------------|----|-----|----|----|
| <b>Chronic Pretreatment</b> | *  | ns  | ns | ns |
| <b>Acute Treatment</b>      | ns | *** | ns | ns |
| <b>Interaction</b>          | ns | ns  | ns | ns |


45x13mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






46x14mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



73x60mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



196x484mm (300 x 300 DPI)